Q-omics provides the consensus-scored GUSBP4 profile across patient tissues and cancer cell-line models. GUSBP4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GUSBP4 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, GUSBP4 RNA expression shows 19,736 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KICH, and THYM as cancer lineages where GUSBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP4 survival associations across molecular data types. GUSBP4 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP4 RNA expression–survival associations across cancer types. High GUSBP4 expression shows favorable associations in UCS, HNSC, LUAD, THYM, LGG and CHOL. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for GUSBP4 RNA expression.
This table summarizes GUSBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP4 shows lower tumor expression in KICH, THCA, BRCA and UCEC and higher tumor expression in KIRC and LIHC. The KICH box plot shows higher GUSBP4 RNA expression in normal versus tumor tissue (log2 FC = −0.781, t-test p < 0.001).
This table shows molecular features associated with GUSBP4 in patient tissues and cancer cell lines. In patient samples, GUSBP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
